Pediatric TransplantArchives
Progress in Noninvasive Surveillance for Acute Rejection in Pediatric Heart Transplant Recipients: A Real‐World Analysis of Donor‐Derived Cell‐Free DNA‐Based Surveillance Protocol
Pediatric Transplant 4 min.
Frequent monitoring of graft function in heart transplant (HT) recipients is vital to identifying acute rejection (AR) in a timely manner. Endomyocardial biopsy (EMB) is traditionally considered the gold standard for surveillance and detection of AR in both pediatric and adult HT patients; however, it...
Changes in Medication Adherence Across the Posttransplant Period in Pediatric Organ Transplant Recipients
Pediatric Transplant 3 min.
Nonadherence to immunosuppressive medication remains a primary concern despite the medical advances in care for pediatric transplant recipients [1, 2]. Nonadherence is predictive of poor health outcomes among pediatric patients, with adolescents and young adults being especially at risk [3–6]....
Donor-derived cell-free DNA testing in pediatric kidney transplant recipients: indications and clinical utility
Pediatric Transplant 8 min.
Long-term kidney transplant survival among pediatric recipients is limited due to complex injurious factors which are both immunologic and non-immunologic [1, 2]. Judicious monitoring for allograft injury and optimization of immunosuppressive therapies are essential for successful long-term outcomes....
Utilization of Hepatitis C Virus‐Infected Donor Hearts in Two Children and Two Young Adults: Initial Experience at a Pediatric Transplant Center
Pediatric Transplant 4 min.
There is a known shortage of available donor hearts, and mortality rates while waiting for heart transplantation are substantial. The overall waitlist mortality is estimated at 17% for pediatric heart transplant recipients, but rises to over 30% in certain high‐risk populations [1]. As transplant...
Association Between High Sensitivity Troponin I and NTproBNP With Rejection and Graft Loss in Pediatric Heart Transplant Recipients
Pediatric Transplant 4 min.
Surveillance endomyocardial biopsy (EMB) after pediatric heart transplantation (HT) in the absence of clinical or laboratory concerns for rejection is costly, invasive, and rarely identifies clinically significant acute rejection after the first post‐transplant year [1, 2]. Reliable, non‐invasive...
